Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Encompass Health Corporation $EHC

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. increased its holdings in Encompass Health Corporation by 80.8% in Q1, acquiring 4,396 additional shares, bringing its total to 9,836 shares valued at approximately $992,000.
• Encompass Health recently reported earnings per share of $1.40, surpassing analysts' expectations, with revenue increasing by 12.0% year-over-year.
• The company announced a quarterly dividend increase to $0.19 per share, with an annualized yield of 0.6%, payable on October 15th.

Banco Bilbao Vizcaya Argentaria S.A. grew its position in shares of Encompass Health Corporation (NYSE:EHC - Free Report) by 80.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,836 shares of the company's stock after purchasing an additional 4,396 shares during the period. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Encompass Health were worth $992,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. OneDigital Investment Advisors LLC purchased a new position in shares of Encompass Health during the 1st quarter valued at $263,000. GAMMA Investing LLC lifted its holdings in shares of Encompass Health by 21.5% during the 1st quarter. GAMMA Investing LLC now owns 2,366 shares of the company's stock worth $240,000 after acquiring an additional 419 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Encompass Health by 6.7% during the 1st quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company's stock worth $276,000 after acquiring an additional 172 shares during the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of Encompass Health by 30.1% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 9,597 shares of the company's stock worth $972,000 after acquiring an additional 2,218 shares during the last quarter. Finally, Fifth Third Bancorp lifted its holdings in shares of Encompass Health by 88.7% during the 1st quarter. Fifth Third Bancorp now owns 4,290 shares of the company's stock worth $434,000 after acquiring an additional 2,017 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Stock Down 0.5%

Shares of Encompass Health stock opened at $122.76 on Friday. The company has a market cap of $12.36 billion, a price-to-earnings ratio of 24.02, a price-to-earnings-growth ratio of 2.16 and a beta of 0.86. The company's 50 day moving average is $116.38 and its 200 day moving average is $110.27. Encompass Health Corporation has a twelve month low of $87.85 and a twelve month high of $124.67. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported $1.40 earnings per share for the quarter, beating analysts' consensus estimates of $1.20 by $0.20. The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.43 billion. Encompass Health had a net margin of 9.22% and a return on equity of 17.83%. The firm's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.11 earnings per share. Encompass Health has set its FY 2025 guidance at 5.120-5.340 EPS. Research analysts anticipate that Encompass Health Corporation will post 4.8 EPS for the current year.

Encompass Health Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Wednesday, October 1st will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a yield of 0.6%. This is a positive change from Encompass Health's previous quarterly dividend of $0.17. The ex-dividend date is Wednesday, October 1st. Encompass Health's payout ratio is currently 14.87%.

Wall Street Analyst Weigh In

Several analysts have weighed in on EHC shares. Truist Financial boosted their price target on shares of Encompass Health from $135.00 to $140.00 and gave the stock a "buy" rating in a research note on Thursday, August 14th. Wall Street Zen cut shares of Encompass Health from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Stephens upgraded shares of Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target on the stock in a research report on Thursday, June 5th. KeyCorp upped their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a report on Tuesday, May 27th. Finally, Royal Bank Of Canada upped their price objective on shares of Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. One analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the stock. According to MarketBeat, Encompass Health has a consensus rating of "Buy" and a consensus price target of $134.00.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.